A study conducted in China during the early weeks of the pandemic found few eyeglass wearers among hospitalized COVID-19 cases.
The outside surfaces of the eye — the conjunctiva, the limbus, the cornea — are laden with the angiotensin-converting enzyme 2 (ACE2) receptors that the SARS-CoV-2 latches on to enter the human body. Whether the eyes actually serve as an entry point for the virus that causes COVID-19 remains an open question, but it is certainly plausible.
So when a study in the most recent issue of JAMA Ophthalmology found that eyeglasses might be protective against COVID-19 infection, it wasn’t far-fetched.
At the same time, a correlation seen in a single observational study cannot prove causation. And an accompanying editorial cautioned against jumping to a conclusion based on these results.
The study by Weibiao Zeng and colleagues was conducted at Suizhou Zengdu Hospital, a designated COVID-19 treatment hospital about 100 miles northwest of Wuhan, where the pandemic is believed to have started. Of the 276 patients with COVID-19 that were enrolled in the study, only 16 (5.8%) wore eyeglasses for more than eight hours a day, a much lower than eyeglass wearers than the 31.5% in the general population of the province.
“Our main finding was that the patients with COVID-19 who wear eyeglasses for an extended period (>8 h/d) every day were relatively uncommon, which could be preliminary evidence that daily wearers of eyeglasses less susceptible to COVID-19,” wrote Zeng and colleagues.
In the accompanying editorial, Lisa Maragakis, M.D., M.P.H., an infectious disease expert at Johns Hopkins University School of Medicine, acknowledged the temptation to conclude that everyone should wear eyeglasses, goggles, or a face shield to protect themselves. But Maragakis invoked to some standard of considerations when it comes to results of studies such as this, including unidentified confounding variables.
She also noted that the proportion for the comparison group came from a study conducted decades ago in a different part of China.
Still, Maragakis acknowledged the possibility that eyeglasses may serve as a “partial barrier that reduces the inoculum of the virus in manner similar to what has been observed for cloth masks.”
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Positive Long-term Results Seen with Vabysmo in Retinal Vein Occlusion
October 10th 2023The FDA is currently reviewing a supplemental biologics license application for Vabysmo in patients with macular edema due to retinal vein occlusion. A decision from the FDA is expected in late 2023.
Read More
The authors of a case series reported in today's edition of JAMA Ophthalmology say silicone oil droplets from silicone used to lubricate the McKesson syringes is the most likely cause of the droplets presumed to cause the floaters. Of the 55 patients treated with Syfovre, 16 developed floaters.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Positive Long-term Results Seen with Vabysmo in Retinal Vein Occlusion
October 10th 2023The FDA is currently reviewing a supplemental biologics license application for Vabysmo in patients with macular edema due to retinal vein occlusion. A decision from the FDA is expected in late 2023.
Read More
The authors of a case series reported in today's edition of JAMA Ophthalmology say silicone oil droplets from silicone used to lubricate the McKesson syringes is the most likely cause of the droplets presumed to cause the floaters. Of the 55 patients treated with Syfovre, 16 developed floaters.
Read More
2 Clarke Drive
Cranbury, NJ 08512